Gene-Therapy Maker Sarepta Tanks After Patient Death The Wall Street JournalSarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying. MarketWatchTeenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies STATSarepta Shares Fall on Report of Patient Death After Gene Therapy BloombergPatient Dies After Receiving Sarepta’s Gene Therapy Barron’s…
Read More